Source 1primary paper2020MED
Toolkit/nanoCRISPR
nanoCRISPR
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
nanoCRISPR is a light-responsive genome-editing nanosystem composed of a cationic polymer-coated gold nanorod (APC) and a Cas9 plasmid driven by a heat-inducible promoter. It is designed to couple near-infrared photothermal stimulation to regulated Cas9 expression for programmable genome editing.
Usefulness & Problems
Why this is useful
The available evidence indicates that nanoCRISPR links a near-infrared-responsive nanomaterial with inducible Cas9 expression, enabling externally controlled genome-editing activity. The source material provided does not supply quantitative performance data or comparative benchmarks.
Source:
The NIR-II optical feature of nanoCRISPR enables deep-tissue therapeutic genome editing, with proof-of-concept treatment of deep tumor and rescue of fulminant hepatic failure.
Source:
This paper reports nanoCRISPR, an optogenetically activatable CRISPR-Cas9 nanosystem for programmable genome editing in the NIR-II optical window.
Problem solved
nanoCRISPR is intended to solve the problem of regulating CRISPR-Cas9 genome editing with a light-triggered input by converting photothermal stimulation into heat-inducible Cas9 expression. The supplied evidence does not further specify target loci, cell types, or editing outcomes.
Source:
The NIR-II optical feature of nanoCRISPR enables deep-tissue therapeutic genome editing, with proof-of-concept treatment of deep tumor and rescue of fulminant hepatic failure.
Published Workflows
Near-infrared optogenetic engineering of photothermal nanoCRISPR for programmable genome editing.
2020Objective: Engineer a remotely controllable CRISPR-Cas9 nanosystem for programmable, spatiotemporally precise genome editing in vitro and in vivo, including deep-tissue therapeutic applications.
Why it works: The abstract states that APC delivers the Cas9 plasmid intracellularly and converts external NIR-II photonic energy into local heat, which induces Cas9 expression from a heat-inducible promoter. This coupling is presented as enabling programmable activation, deep-tissue access, and reduced off-target editing.
NIR-II photothermal conversion to local heatheat-inducible Cas9 expressionlight-programmed temporal control of editingnanoparticle-mediated plasmid deliveryoptogenetic activationexternal irradiation tuning
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A composed arrangement of multiple parts that instantiates one or more mechanisms.
Techniques
No technique tags yet.
Target processes
editingInput: Light
Implementation Constraints
nanoCRISPR includes APC, described as a cationic polymer-coated gold nanorod, together with a Cas9 plasmid under a heat-inducible promoter. The system is associated with near-infrared photothermal stimulation, but the supplied evidence does not specify promoter identity, irradiation parameters, plasmid architecture, or delivery conditions.
The evidence set is limited to composition-level description from a single cited study and does not provide direct data on editing efficiency, specificity, reversibility, toxicity, or in vivo performance. Independent replication is not documented in the supplied material.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
nanoCRISPR is composed of APC and a Cas9 plasmid driven by a heat-inducible promoter.
nanoCRISPR is composed of APC and a Cas9 plasmid driven by a heat-inducible promoter.
nanoCRISPR is composed of APC and a Cas9 plasmid driven by a heat-inducible promoter.
nanoCRISPR is composed of APC and a Cas9 plasmid driven by a heat-inducible promoter.
nanoCRISPR is composed of APC and a Cas9 plasmid driven by a heat-inducible promoter.
nanoCRISPR is composed of APC and a Cas9 plasmid driven by a heat-inducible promoter.
nanoCRISPR is composed of APC and a Cas9 plasmid driven by a heat-inducible promoter.
nanoCRISPR is composed of APC and a Cas9 plasmid driven by a heat-inducible promoter.
Genome-editing activity of nanoCRISPR can be programmed by tuning exposure time and irradiation time in vitro and in vivo and can be triggered at multiple time points.
Genome-editing activity of nanoCRISPR can be programmed by tuning exposure time and irradiation time in vitro and in vivo and can be triggered at multiple time points.
Genome-editing activity of nanoCRISPR can be programmed by tuning exposure time and irradiation time in vitro and in vivo and can be triggered at multiple time points.
Genome-editing activity of nanoCRISPR can be programmed by tuning exposure time and irradiation time in vitro and in vivo and can be triggered at multiple time points.
Genome-editing activity of nanoCRISPR can be programmed by tuning exposure time and irradiation time in vitro and in vivo and can be triggered at multiple time points.
Genome-editing activity of nanoCRISPR can be programmed by tuning exposure time and irradiation time in vitro and in vivo and can be triggered at multiple time points.
Genome-editing activity of nanoCRISPR can be programmed by tuning exposure time and irradiation time in vitro and in vivo and can be triggered at multiple time points.
Genome-editing activity of nanoCRISPR can be programmed by tuning exposure time and irradiation time in vitro and in vivo and can be triggered at multiple time points.
APC functions as both an intracellular plasmid carrier and a photothermal transducer that converts external NIR-II light into local heat to induce Cas9 expression.
APC functions as both an intracellular plasmid carrier and a photothermal transducer that converts external NIR-II light into local heat to induce Cas9 expression.
APC functions as both an intracellular plasmid carrier and a photothermal transducer that converts external NIR-II light into local heat to induce Cas9 expression.
APC functions as both an intracellular plasmid carrier and a photothermal transducer that converts external NIR-II light into local heat to induce Cas9 expression.
APC functions as both an intracellular plasmid carrier and a photothermal transducer that converts external NIR-II light into local heat to induce Cas9 expression.
APC functions as both an intracellular plasmid carrier and a photothermal transducer that converts external NIR-II light into local heat to induce Cas9 expression.
APC functions as both an intracellular plasmid carrier and a photothermal transducer that converts external NIR-II light into local heat to induce Cas9 expression.
APC functions as both an intracellular plasmid carrier and a photothermal transducer that converts external NIR-II light into local heat to induce Cas9 expression.
Upon optogenetic activation, APC-mediated nanoCRISPR induces significant disruption at different genomic loci.
Upon optogenetic activation, APC-mediated nanoCRISPR induces significant disruption at different genomic loci.
Upon optogenetic activation, APC-mediated nanoCRISPR induces significant disruption at different genomic loci.
Upon optogenetic activation, APC-mediated nanoCRISPR induces significant disruption at different genomic loci.
Upon optogenetic activation, APC-mediated nanoCRISPR induces significant disruption at different genomic loci.
Upon optogenetic activation, APC-mediated nanoCRISPR induces significant disruption at different genomic loci.
Upon optogenetic activation, APC-mediated nanoCRISPR induces significant disruption at different genomic loci.
Upon optogenetic activation, APC-mediated nanoCRISPR induces significant disruption at different genomic loci.
This optogenetic genome-editing modality significantly minimizes CRISPR-Cas9 off-target effects at most potential off-target sites.
This optogenetic genome-editing modality significantly minimizes CRISPR-Cas9 off-target effects at most potential off-target sites.
This optogenetic genome-editing modality significantly minimizes CRISPR-Cas9 off-target effects at most potential off-target sites.
This optogenetic genome-editing modality significantly minimizes CRISPR-Cas9 off-target effects at most potential off-target sites.
This optogenetic genome-editing modality significantly minimizes CRISPR-Cas9 off-target effects at most potential off-target sites.
This optogenetic genome-editing modality significantly minimizes CRISPR-Cas9 off-target effects at most potential off-target sites.
This optogenetic genome-editing modality significantly minimizes CRISPR-Cas9 off-target effects at most potential off-target sites.
This optogenetic genome-editing modality significantly minimizes CRISPR-Cas9 off-target effects at most potential off-target sites.
The NIR-II optical feature of nanoCRISPR enables deep-tissue therapeutic genome editing, with proof-of-concept treatment of deep tumor and rescue of fulminant hepatic failure.
The NIR-II optical feature of nanoCRISPR enables deep-tissue therapeutic genome editing, with proof-of-concept treatment of deep tumor and rescue of fulminant hepatic failure.
The NIR-II optical feature of nanoCRISPR enables deep-tissue therapeutic genome editing, with proof-of-concept treatment of deep tumor and rescue of fulminant hepatic failure.
The NIR-II optical feature of nanoCRISPR enables deep-tissue therapeutic genome editing, with proof-of-concept treatment of deep tumor and rescue of fulminant hepatic failure.
The NIR-II optical feature of nanoCRISPR enables deep-tissue therapeutic genome editing, with proof-of-concept treatment of deep tumor and rescue of fulminant hepatic failure.
The NIR-II optical feature of nanoCRISPR enables deep-tissue therapeutic genome editing, with proof-of-concept treatment of deep tumor and rescue of fulminant hepatic failure.
The NIR-II optical feature of nanoCRISPR enables deep-tissue therapeutic genome editing, with proof-of-concept treatment of deep tumor and rescue of fulminant hepatic failure.
The NIR-II optical feature of nanoCRISPR enables deep-tissue therapeutic genome editing, with proof-of-concept treatment of deep tumor and rescue of fulminant hepatic failure.
This paper reports nanoCRISPR, an optogenetically activatable CRISPR-Cas9 nanosystem for programmable genome editing in the NIR-II optical window.
This paper reports nanoCRISPR, an optogenetically activatable CRISPR-Cas9 nanosystem for programmable genome editing in the NIR-II optical window.
This paper reports nanoCRISPR, an optogenetically activatable CRISPR-Cas9 nanosystem for programmable genome editing in the NIR-II optical window.
This paper reports nanoCRISPR, an optogenetically activatable CRISPR-Cas9 nanosystem for programmable genome editing in the NIR-II optical window.
This paper reports nanoCRISPR, an optogenetically activatable CRISPR-Cas9 nanosystem for programmable genome editing in the NIR-II optical window.
This paper reports nanoCRISPR, an optogenetically activatable CRISPR-Cas9 nanosystem for programmable genome editing in the NIR-II optical window.
This paper reports nanoCRISPR, an optogenetically activatable CRISPR-Cas9 nanosystem for programmable genome editing in the NIR-II optical window.
This paper reports nanoCRISPR, an optogenetically activatable CRISPR-Cas9 nanosystem for programmable genome editing in the NIR-II optical window.
Approval Evidence
1 source6 linked approval claimsfirst-pass slug nanocrispr
The nanosystem, termed nanoCRISPR, is composed of a cationic polymer-coated Au nanorod (APC) and Cas9 plasmid driven by a heat-inducible promoter.
Source:
compositionsupports
nanoCRISPR is composed of APC and a Cas9 plasmid driven by a heat-inducible promoter.
Source:
controllabilitysupports
Genome-editing activity of nanoCRISPR can be programmed by tuning exposure time and irradiation time in vitro and in vivo and can be triggered at multiple time points.
Source:
performancesupports
Upon optogenetic activation, APC-mediated nanoCRISPR induces significant disruption at different genomic loci.
Source:
specificitysupports
This optogenetic genome-editing modality significantly minimizes CRISPR-Cas9 off-target effects at most potential off-target sites.
Source:
therapeutic applicationsupports
The NIR-II optical feature of nanoCRISPR enables deep-tissue therapeutic genome editing, with proof-of-concept treatment of deep tumor and rescue of fulminant hepatic failure.
Source:
tool introductionsupports
This paper reports nanoCRISPR, an optogenetically activatable CRISPR-Cas9 nanosystem for programmable genome editing in the NIR-II optical window.
Source:
Comparisons
Source-backed strengths
Its defining strength is the integration of a cationic polymer-coated gold nanorod carrier with a heat-inducible Cas9 plasmid in a single multi-component system. This architecture supports a conceptually programmable connection between near-infrared light exposure and genome-editing control, but the provided evidence does not include validation metrics.
Source:
Upon optogenetic activation, APC-mediated nanoCRISPR induces significant disruption at different genomic loci.
Ranked Citations
- 1.